Product Details
Synonyms [(S)-1-Carboxy-2-phenylethyl]-carbamoyl-Arg-Val-arginal . 2HCl
Product Type Chemical
Properties
Formula
C27H44N10O6 . 2HCl
MW 604.7 . 72.9
CAS 37682-72-7
RTECS YV9350800
Source/Host Chemicals Synthetic.
Purity Chemicals ≥97% (HPLC)
Appearance White to off-white solid.
Solubility Soluble in water, ethanol, methanol, DMSO or acetonitrile.
Biological Activity
Inhibitory Activity: ≥30 U/mg (Trypsin, L-BAPA)
InChi Key YAHXZYICKJUJEO-BXLPLHKWSA-N
Smiles [Cl-].[Cl-].[H]C(=O)C(CCCNC(N)=[NH2+])NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)NC(CC1=CC=CC=C1)C(O)=O)C(C)C
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Protect from light and moisture.
Use/Stability Stable for at least 3 years after receipt when stored at -20°C.
Antipain, a new protease inhibitor isolated from actinomycetes: H. Suda, et al.; J. Antibiot. 25, 263 (1972)
Structures and activities of protease inhibitors of microbial origin: H. Umezawa; Methods Enzymol. 45, 678 (1976)
Inhibition of proteolytic activity of calcium activated neutral protease by leupeptin and antipain: T. Toyo-Oka, et al.; BBRC 82, 484 (1978)
Effects of antipain (a protease inhibitor) on respiration, viability, and excision of pyrimidine dimers in UV-irradiated Escherichia coli cells: P.A. Swenson & R.L. Schenley; J. Bacteriol. 135, 1167 (1978)
Effect of Ca2+ on the inhibition of calcium-activated neutral protease by leupeptin, antipain and epoxysuccinate derivatives: K. Suzuki, et al.; FEBS Lett. 136, 119 (1981)
Inhibition of Leishmania amastigote growth by antipain and leupeptin: G.H. Coombs & J. Baxter; Ann. Trop. Med. Parasitol. 78, 21 (1984)
Antipain or leupeptin in combination with aspirin or indomethacin synergistically inhibit human platelet activation by thrombin and trypsin: M. Ruggiero & E.G. Lapetina; Adv. Prostaglandin Thromboxane Leukot. Res. 17A, 563 (1987)
Inhibition of H-ras oncogene transformation of NIH3T3 cells by protease inhibitors: S.J. Garte, et al.; Cancer Res. 47, 3159 (1987)
Reversible conversion of tyrosine hydroxylase to an inactive form by antipain: S. Okuno & H. Fujisawa; BBRC 146, 1375 (1987)
Antipain-induced suppression of oncogene expression in H-ras-transformed NIH3T3 cells: L.R. Cox, et al.; Cancer Res. 51, 4810 (1991)
Effects of the protease inhibitor antipain on cell malignant transformation: M. Vaccari, et al.; Anticancer Res. 19, 589 (1999)
Lysosomes, growth factor activity, and carcinogenic implications: M. Melzer; Crit. Rev. Eukaryot. Gene. Expr. 22, 345 (2012)